Premium
Molecularly targeted therapy for melanoma
Author(s) -
Becker Jürgen C.,
Kirkwood John M.,
Agarwala Sanjiv S.,
Dummer Reinhard,
Schrama David,
Hauschild Axel
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22273
Subject(s) - medicine , melanoma , targeted therapy , cancer research , protein kinase b , pi3k/akt/mtor pathway , signal transduction , cancer , angiogenesis , radiation therapy , mapk/erk pathway , bioinformatics , oncology , biology , genetics
Effective therapy for melanoma remains an unmet goal, with most traditional therapies representing inadequate trade‐offs among the several goals of specificity, efficacy, and toxicity. Targeted molecular therapeutics are tailored to genetic abnormalities that are associated with tumor progression. Modulation of aberrant signaling pathways in cancer cells has the potential to provide more effective and potentially nontoxic therapy for a broad range of cancers, including melanoma. Among the possible targets in melanoma are the Ras‐MAPK and PI3K/AKT signal transduction pathways, the proteasome, histone deacetylases, methyltransferases, and melanoma‐induced angiogenesis. Cancer 2006. © 2006 American Cancer Society.